Abstract
Human serum albumin nanoparticles (HSA-PNPs) have emerged as promising nanocarriers for drug delivery, particularly in cancer therapy. Their advantages include ease of synthesis, versatility, biocompatibility, and interactions with SPARC - a glycoprotein overexpressed in the extracellular matrix of tumors. SPARC is associated with tumor aggressiveness and metastasis in certain cancers, ma…